Tarsus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Tarsus Pharmaceuticals

09/11/2022 12:13

* Tarsus Pharmaceuticals Inc  TARS.OQ  reported a quarterly
adjusted loss of 84 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 97 cents per share.
    * Reported revenue was zero​; analysts expected $2.92
million. 
    * Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 84 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Tarsus Pharmaceuticals Inc shares had risen by 5.4% this
quarter and lost 19.8% so far this year.
    * The company reported a quarterly loss of $22.51 million.
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $45.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 12:13 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.97          -0.84          Beat
 Jun. 30 2022      -0.59          -0.24          Beat
 Mar. 31 2022      -0.92          -0.98          Missed
 Dec. 31 2021      -0.73          -0.72          Beat